Arbutus Biopharma Corporation Common Stock
ABUSArbutus Biopharma Corporation is a biopharmaceutical company focused on developing therapies for viral diseases, particularly hepatitis B virus (HBV). The company leverages its proprietary delivery technologies to create targeted treatments aimed at curing chronic HBV infections. Established with a focus on innovative antiviral solutions, Arbutus Biopharma aims to address unmet medical needs in infectious diseases.
Company News
Moderna's stock has been struggling since the end of the COVID-19 pandemic, with a Wall Street analyst cutting her price target and reiterating a sell recommendation. The analyst cited issues such as cost-management struggles and legal headaches, as well as a hold on a late-stage trial for a norovirus vaccine candidate.
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment
WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will present at and host ...
